Press release
Proliferative vitreoretinopathy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics
Proliferative vitreoretinopathy Pipeline Analysis 2025 by DelveInsight
Proliferative vitreoretinopathy Overview:
Proliferative Vitreoretinopathy (PVR) is a rare eye condition that can result in vision loss or blindness. It typically develops after retinal detachment surgery or from an open globe injury (eye trauma). In PVR, retinal cells proliferate and form scar tissue, which then contracts and pulls the retina away. There is currently no approved treatment for PVR, which causes 75% of complications following retinal detachment and affects 5-10% of individuals who undergo retinal detachment surgery. It can also occur in up to 50% of those who experience an open globe injury.
Download our report @ https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Proliferative vitreoretinopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Proliferative vitreoretinopathy Therapeutics Market.
Key Takeaways from the Proliferative vitreoretinopathy Pipeline Report
DelveInsight's Proliferative vitreoretinopathy pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Proliferative vitreoretinopathy treatment.
Aldeyra Therapeutics is advancing ADX-2191, a preservative-free, intravitreal formulation of methotrexate, for the prevention of PVR. In 2018, the FDA granted ADX-2191 Orphan Drug Designation for PVR prevention. The Phase 3 GUARD trial demonstrated that ADX-2191 was statistically superior to historical controls in preventing retinal detachment and showed numerical superiority over routine surgical care in several secondary endpoints. The drug was well-tolerated, with no serious adverse events reported. In 2023, Aldeyra planned to hold a Type C meeting with the FDA to discuss the completion of clinical development for ADX-2191 in PVR prevention.
Key Proliferative vitreoretinopathy companies such as Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics, and others are evaluating new drugs for Proliferative vitreoretinopathy to improve the treatment landscape.
Promising Proliferative vitreoretinopathy therapies include ADX-2191, PPP-003, and others.
Proliferative vitreoretinopathy Pipeline Analysis
The Proliferative vitreoretinopathy pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Proliferative vitreoretinopathy Market.
Categorizes Proliferative vitreoretinopathy therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Proliferative vitreoretinopathy drugs under development based on:
Stage of development
Proliferative vitreoretinopathy Route of administration
Target receptor
Monotherapy vs. combination therapy
Proliferative vitreoretinopathy Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Proliferative vitreoretinopathy Licensing agreements
Funding and investment activities supporting future Proliferative vitreoretinopathy market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Proliferative vitreoretinopathy Emerging Drugs
ADX-2191: Aldeyra Therapeutics
ADX-2191, an intravitreal formulation of methotrexate, has received Orphan Drug Designation for preventing Proliferative Vitreoretinopathy (PVR). Its clinical effectiveness in PVR patients is thought to stem from the inhibition of abnormal retinal cell proliferation and activity, leading to reduced retinal scarring associated with the condition. Aldeyra holds an exclusive license for certain patents concerning the use of ADX-2191 in PVR prevention.
PPP-003: Tetra Bio-Pharma
PPP003 (HU308) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for preventing Proliferative Vitreoretinopathy.
Proliferative vitreoretinopathy Companies
Around 3 or more key companies are working on therapies for Proliferative Vitreoretinopathy. Aldeyra Therapeutics is among the companies with drug candidates for this condition in the most advanced stage, namely Phase III.
DelveInsight's report covers around 100+ products under different phases of Proliferative vitreoretinopathy clinical trials like
Proliferative vitreoretinopathy Late stage Therapies (Phase III)
Proliferative vitreoretinopathy Mid-stage Therapies (Phase II)
Proliferative vitreoretinopathy Early-stage Therapies (Phase I)
Proliferative vitreoretinopathy Pre-clinical and Proliferative vitreoretinopathy Discovery stage Therapies
Proliferative vitreoretinopathy Discontinued & Inactive Therapies
Proliferative vitreoretinopathy pipeline report provides the Proliferative vitreoretinopathy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Proliferative vitreoretinopathy Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Proliferative vitreoretinopathy Therapies and Key Proliferative vitreoretinopathy Companies: Proliferative vitreoretinopathy Clinical Trials and recent advancements https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Proliferative vitreoretinopathy Pipeline Therapeutic Assessment
• Proliferative vitreoretinopathy Assessment by Product Type
• Proliferative vitreoretinopathy By Stage
• Proliferative vitreoretinopathy Assessment by Route of Administration
• Proliferative vitreoretinopathy Assessment by Molecule Type
Download Proliferative vitreoretinopathy Sample report to know in detail about the Proliferative vitreoretinopathy treatment market @ Proliferative vitreoretinopathy Therapeutic Assessment https://www.delveinsight.com/sample-request/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Proliferative vitreoretinopathy Current Treatment Patterns
4. Proliferative vitreoretinopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Proliferative vitreoretinopathy Late-Stage Products (Phase-III)
7. Proliferative vitreoretinopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Proliferative vitreoretinopathy Discontinued Products
13. Proliferative vitreoretinopathy Product Profiles
14. Proliferative vitreoretinopathy Key Companies
15. Proliferative vitreoretinopathy Key Products
16. Dormant and Discontinued Products
17. Proliferative vitreoretinopathy Unmet Needs
18. Proliferative vitreoretinopathy Future Perspectives
19. Proliferative vitreoretinopathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Proliferative vitreoretinopathy Pipeline Reports Offerings: https://www.delveinsight.com/report-store/proliferative-vitreoretinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Proliferative vitreoretinopathy Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics here
News-ID: 3989833 • Views: …
More Releases from DelveInsight Business Research LLP
Presbyopia Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsigh …
Presbyopia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Presbyopia treatment therapies, analyzes DelveInsight.
Presbyopia Overview:
Presbyopia is an age-related condition in which the eye's lens loses its ability to focus on nearby objects. It is the most common physiological change seen in adults and typically results in difficulty with near vision. People with presbyopia often experience eye strain and headaches, and may hold objects further away to see them…
Vernal keratoconjunctivitis Pipeline Analysis and Clinical Trials Assessment, 20 …
Vernal keratoconjunctivitis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Vernal keratoconjunctivitis treatment therapies, analyzes DelveInsight.
Vernal keratoconjunctivitis Overview:
Vernal Keratoconjunctivitis (VKC) is a rare, chronic ocular allergy that can lead to serious vision issues. It primarily affects children and young adults and is an IgE- and T cell-mediated disorder that causes persistent inflammation with involvement from eosinophils, lymphocytes, and structural cells. Treating VKC requires a combination of conservative measures…
Ocular inflammation and pain Pipeline Analysis and Clinical Trials Assessment, 2 …
Ocular inflammation and pain Pipeline constitutes 5+ key companies continuously working towards developing 5+ Ocular inflammation and pain treatment therapies, analyzes DelveInsight.
Ocular inflammation and pain Overview:
Inflammation is the body's natural response to injury, infection, or irritation. In some cases, it can occur due to harmless substances, like dust, pollen, or grass, leading to an allergic reaction. The immune system may also cause inflammation when it mistakenly attacks the body's own…
X-linked retinitis pigmentosa Pipeline Analysis and Clinical Trials Assessment, …
X-linked retinitis pigmentosa Pipeline constitutes 5+ key companies continuously working towards developing 5+ X-linked retinitis pigmentosa treatment therapies, analyzes DelveInsight.
X-linked retinitis pigmentosa Overview:
X-linked Retinitis Pigmentosa is a rare hereditary genetic disorder caused by a mutation in the X chromosome. It leads to the gradual degeneration of photoreceptor cells in the retina, resulting in progressive loss of peripheral vision. The condition affects approximately 1 in 4,000 people globally. Because it is…
More Releases for Proliferative
Global Proliferative Diabetic Retinopathy Research and Market Analysis 2018
ResearchMoz include new market research report "Proliferative Diabetic Retinopathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026" to its huge collection of research reports.
Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The…
Proliferative Vitreoretinopathy Market: Global Trends, Analysis and Forecast 202 …
Proliferative vitreoretinopathy (PVR) remains the most commonly observed failure in the surgery of rhegmatogenous retinal detachment (RRD), albeit substantial efforts have been taken to better understand and manage the condition in the past. Basic research indicates that proliferative vitreoretinopathy illustrates scarring - end-stage of wound healing process, which occurs post-retinal detachment surgery. Current medical treatment for PVR has been directed toward the prevention of inflammation – first stage of wound-healing…
Proliferative Vitreoretinopathy Market to Remain Lucrative During 2027
The most frequent and traumatic complication faced post-rhegmatogenous retinal detachment (RRD), proliferative vitreoretinopathy (PVR) continues to be a bottleneck in developing new surgical techniques for diseases related to retina such as retinal pigment epithelium transplantation, and macular translocation. Posterior contraction of the membranes formed on either sides of retina that are a result of PVR, and shortening of retina are key complications that prevent reattachment of retina.
Report overview @ https://www.xploremr.com/report/1499/proliferative-vitreoretinopathy-market
Complex…
Proliferative Diabetic Retinopathy-Pipeline Review H2 2018
Proliferative Diabetic Retinopathy (PDR)-Pipeline Review, H2 2018
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR)-Pipeline Review, H2 2018, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop…
Proliferative Vitreoretinopathy Market Estimated to Exhibit 4% CAGR through 2027
About Proliferative Vitreoretinopathy Market
With the rise in emphasis on prevention and treatment of proliferative vitreoretinopathy (PVR), a serious ailment that leads to blindness despite repeated treatment, the requirement for vitreoretinal centers has gained importance worldwide. Prevention of PVR development at early stage RRD for preserving visual function in patients has become a primary agenda among medical researchers and clinicians. A recent Fact.MR analysis envisages the proliferative vitreoretinopathy market to…
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H2 2017, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue…
